Healthcare Professional Information
Echo Therapeutics Pty Ltd (Echo Therapeutics) is the registered sponsor of a number of pharmaceutical products in Australia, including Pegasys (peginterferon alfa-2a). Pegasys is currently listed on the Pharmaceutical Benefits Scheme (PBS) as a treatment for Hepatitis C (Streamlined Authority) and Antineoplastic Immunotherapy (General Schedule). Australian patients with Myeloproliferative Neoplasms (MPNs), a group of rare blood disorders, have been able to access Pegasys reimbursed through this general PBS listing when prescribed by their treating haematologist. It is supplied to retail pharmacies and hospitals via wholesalers.
As a treating clinician of Australians living with MPN, I wanted to update you on some important changes that will impact how your patients receive Pegasys moving forward.
What does this mean for patients?
From 1 September 2024, Australian patients are only able to access Pegasys through our new dedicated Pegasys Home Delivery Program, coordinated by JustMeds.
Please find below information and the steps to how to arrange delivery of Pegasys (peginterferon alfa-2a) for your patients. Communication available to patients and healthcare professionals. Click here
To contact the JustMeds team directly, please Click here or call on 07 2000 4124.